Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06880549 · ClinicalTrials.gov registry record · Phase 1

A Study of mRNA-4106 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Solid Tumors

A Phase 1 study of Advanced Solid Tumors, sponsored by ModernaTX.

Active
Registry status
Phase 1
Development phase
57
Enrollment target
3
Study locations

NCT06880549 is a Phase 1 study of Advanced Solid Tumors that is active but no longer recruiting, run by ModernaTX. The registered enrollment target is 57 participants, below the 198-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (71% lower). The trial reports 3 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06880549, a Phase 1 study of Advanced Solid Tumors, is active but no longer recruiting, sponsored by ModernaTX.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
57 participants
Enrollment target
3
Study locations

Study Summary

The purpose of this study is to assess the safety and tolerability of mRNA-4106 administered alone and in combination with checkpoint inhibitor (CPI) therapy in participants with solid tumors.

Conditions Studied

Advanced Solid Tumors

Interventions

  • BIOLOGICAL mRNA-4106
  • BIOLOGICAL Nivolumab/Relatlimab

Study Locations (3)

Michigan

  • START Midwest - Grand Rapids

Texas

  • START San Antonio - San Antonio

Utah

  • START Mountain Region - West Valley City

Trial Details

FieldValue
Enrollment Target 57 participants
Start Date 2025-03-25
Est. Completion 2029-01-10
Phase Phase 1

Sponsor

ModernaTX

90 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06880549

The ClinicalTrials.gov registry entry for NCT06880549 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 57 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 198-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (71% lower). The listed sponsor is ModernaTX, which has 90 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Advanced Solid Tumors appearing as the primary indexed condition, and to 2 interventions - of which mRNA-4106 is the first listed.

NCT06880549 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Michigan, Texas, Utah.

Frequently Asked Questions

What is clinical trial NCT06880549 about?

NCT06880549 is a clinical study titled "A Study of mRNA-4106 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Solid Tumors". The purpose of this study is to assess the safety and tolerability of mRNA-4106 administered alone and in combination with checkpoint inhibitor (CPI) therapy in participants with solid tumors.

What is the current status of trial NCT06880549?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 57 participants. The study started on 2025-03-25. Estimated completion is 2029-01-10.

What conditions does trial NCT06880549 study?

This clinical trial studies the following conditions: Advanced Solid Tumors.

What interventions are being tested in trial NCT06880549?

The interventions under investigation include: mRNA-4106 (BIOLOGICAL), Nivolumab/Relatlimab (BIOLOGICAL).

Who is sponsoring clinical trial NCT06880549?

This trial is sponsored by ModernaTX, which has 90 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06880549 being conducted?

This trial has 3 study locations across Michigan, Texas, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumors

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Advanced Solid Tumors

All registered trials for this condition

Michigan

All trials with a study site in Michigan

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.